

# ELOCTA® AND ALPROLIX® IN EUROPE: LONG TERM EXPERIENCE AND REAL-WORLD CASES

Sobi™ Satellite Symposium

10<sup>th</sup> Annual Congress of  
the European Association  
for Haemophilia and  
Allied Disorders

Paris, France

Wednesday 1 February 2017, 18:00 – 19:30, Room CDEF, Paris Marriott Rive Gauche Hotel

Dear Colleague,

On behalf of Sobi™, we would like to invite you to the Satellite Symposium which will take place on **Wednesday 1 February 2017 in Room CDEF at the Paris Marriott Rive Gauche Hotel, from 18:00 – 19:30.** We look forward to seeing you at this engaging and informative symposium.

With kind regards,

**Hervé Chambost (Chair)**

Professor, MD, PhD, Marseille, France

**Stefan Lethagen (Co-chair)**

Professor, MD, PhD, Vice President Medical & Clinical Sciences, Haemophilia, Sobi™

## Agenda

18:00 – 18:10	Welcome and Introduction	Stefan Lethagen, Sobi™
18:10 – 18:25	Features of Elocta® and Alprolix®	Hervé Chambost, France
18:25 – 18:45	How I Switched My Patients to Elocta® and Alprolix®: Real-World Cases from Germany	Johannes Oldenburg, Germany
18:45 – 19:05	How I Switched My Patients to Elocta® and Alprolix®: Real-World Cases from the United Kingdom	Pratima Chowdary, United Kingdom
19:05 – 19:25	How I Switched My Patients to Elocta®: Real-World Cases from France	Hervé Chambost, France
19:25 – 19:30	Closing Remarks	Stefan Lethagen, Sobi™

For healthcare professionals only. The content of the symposium may not correspond to the guidelines in your country. Please refer to your local guidelines and prescribing information.



Sobi, Elocta and Alprolix are trademarks of Swedish Orphan Biovitrum AB (publ).  
© 2016 Swedish Orphan Biovitrum AB (publ) – All rights reserved

Swedish Orphan Biovitrum AB (publ)  
SE-112 76 Stockholm, Sweden  
www.sobihaemophilia.com

▼ This medicinal product is subject to additional monitoring  
Elocta® (EMA)  
Alprolix® (EMA)

Date of preparation: December 2016  
PP-1931